Skip to main content
SpringerLink
Log in

The role of statins in the treatment of the metabolic syndrome

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

The metabolic syndrome is a cluster of cardiometabolic risk factors associated with higher risk for atherosclerotic cardiovascular (CV) disease and diabetes. Its prevalence is about 20% to 30% among adults worldwide and is increasing. The primary goal is reduction of CV risk through lifestyle changes and drug therapy if required. Post hoc analyses of prospective trials showed the benefit of lowering low-density lipoprotein (LDL) cholesterol in patients with the metabolic syndrome. Statin therapy exerts beneficial effects not only by lowering LDL cholesterol but also via its so-called pleiotropic effects. These effects seem particularly important for reducing risk of CV disease in patients with the metabolic syndrome. Thus, evidence is accumulating that statins are very effective therapeutic agents in the treatment of individuals with the metabolic syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595–1607.

    Article  PubMed  CAS  Google Scholar 

  2. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a who consultation. Diabet Med 1998, 15:539–553.

    Article  PubMed  CAS  Google Scholar 

  3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.

  4. Alberti KG, Zimmet P, Shaw J: The metabolic syndrome—a new worldwide definition. Lancet 2005, 366:1059–1062.

    Article  PubMed  Google Scholar 

  5. Grundy SM: Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008, 28:629–636.

    Article  PubMed  CAS  Google Scholar 

  6. Wilson PW, D’Agostino RB, Parise H, et al.: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112:3066–3072.

    Article  PubMed  CAS  Google Scholar 

  7. Gami AS, Witt BJ, Howard DE, et al.: Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007, 49:403–414.

    Article  PubMed  CAS  Google Scholar 

  8. Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation 2005, 112:2735–2752.

    Article  PubMed  Google Scholar 

  9. Grundy SM: Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007, 92:399–404.

    Article  PubMed  CAS  Google Scholar 

  10. Cannon CP, Steinberg BA, Murphy SA, et al.: Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006, 48:438–445.

    Article  PubMed  CAS  Google Scholar 

  11. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239.

    Article  PubMed  Google Scholar 

  12. Clearfield M, Downs JR, Lee M, et al.: Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines. Am J Cardiol 2005, 96:1674–1680.

    Article  PubMed  Google Scholar 

  13. Sattar N, Gaw A, Scherbakova O, et al.: Metabolic syndrome with and without c-reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland coronary prevention study. Circulation 2003, 108:414–419.

    Article  PubMed  CAS  Google Scholar 

  14. Pyorala K, Ballantyne CM, Gumbiner B, et al.: Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian simvastatin survival study (4s). Diabetes Care 2004, 27:1735–1740.

    Article  PubMed  CAS  Google Scholar 

  15. Deedwania P, Barter P, Carmena R, et al.: Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the treating to new targets study. Lancet 2006, 368:919–928.

    Article  PubMed  CAS  Google Scholar 

  16. Sasaki S, Kuwahara N, Kunitomo K, et al.: Effects of atorvastatin on oxidized low-density lipoprotein, lowdensity lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol 2002, 89:386–389.

    Article  PubMed  CAS  Google Scholar 

  17. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712–1719.

    Article  PubMed  CAS  Google Scholar 

  18. Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 1999, 340:115–126.

    Article  PubMed  CAS  Google Scholar 

  19. Ridker PM, Rifai N, Rose L, et al.: Comparison of c-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557–1565.

    Article  PubMed  CAS  Google Scholar 

  20. Trayhurn P, Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004, 92:347–355.

    Article  PubMed  CAS  Google Scholar 

  21. Weisberg SP, McCann D, Desai M, et al.: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796–1808.

    PubMed  CAS  Google Scholar 

  22. Gustafson B, Hammarstedt A, Andersson CX, Smith U: Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:2276–2283.

    Article  PubMed  CAS  Google Scholar 

  23. Mora S, Ridker PM: Justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin (JUPITER)-can c-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 2006, 97:33A–41A.

    Article  PubMed  CAS  Google Scholar 

  24. Ridker PM, Wilson PW, Grundy SM: Should c-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004, 109:2818–2825.

    Article  PubMed  CAS  Google Scholar 

  25. Devaraj S, Chan E, Jialal I: Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 2006, 91:4489–4496.

    Article  PubMed  CAS  Google Scholar 

  26. Singh U, Devaraj S, Jialal I, Siegel D: Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol 2008, 102:321–325.

    Article  PubMed  CAS  Google Scholar 

  27. Balk EM, Lau J, Goudas LC, et al.: Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 2003, 139:670–682.

    PubMed  CAS  Google Scholar 

  28. Kinlay S: Low-density lipoprotein-dependent and — independent effects of cholesterol-lowering therapies on c-reactive protein: a meta-analysis. J Am Coll Cardiol 2007, 49:2003–2009.

    Article  PubMed  CAS  Google Scholar 

  29. Vane JR, Anggard EE, Botting RM: Regulatory functions of the vascular endothelium. N Engl J Med 1990, 323:27–36.

    PubMed  CAS  Google Scholar 

  30. Govers R, Rabelink TJ: Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 2001, 280:F193–206.

    PubMed  CAS  Google Scholar 

  31. Werns SW, Walton JA, Hsia HH, et al.: Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation 1989, 79:287–291.

    PubMed  CAS  Google Scholar 

  32. Koh KK, Han SH, Quon MJ: Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 2005, 46:1978–1985.

    Article  PubMed  CAS  Google Scholar 

  33. Wolfrum S, Jensen KS, Liao JK: Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003, 23:729–736.

    Article  PubMed  CAS  Google Scholar 

  34. John S, Schlaich M, Langenfeld M, et al.: Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 1998, 98:211–216.

    PubMed  CAS  Google Scholar 

  35. Perticone F, Ceravolo R, Maio R, et al.: Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients. Atherosclerosis 2000, 152:511–518.

    Article  PubMed  CAS  Google Scholar 

  36. John S, Schneider MP, Delles C, et al.: Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005, 149:473.

    Article  PubMed  Google Scholar 

  37. Ott C, Schlaich MP, Schmidt BM, et al.: Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis 2008, 196:704–711.

    Article  PubMed  CAS  Google Scholar 

  38. Oguz A, Uzunlulu M: Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome. Int Heart J 2008, 49:303–311.

    Article  PubMed  CAS  Google Scholar 

  39. Anderson TJ: Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999, 34:631–638.

    Article  PubMed  CAS  Google Scholar 

  40. Chen J, Muntner P, Hamm LL, et al.: The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004, 140:167–174.

    PubMed  Google Scholar 

  41. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al.: Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. Nephrol Dial Transplant 2007, 22:118–127.

    Article  PubMed  CAS  Google Scholar 

  42. Geluk CA, Asselbergs FW, Hillege HL, et al.: Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the prevend intervention trial. Eur Heart J 2005, 26:1314–1320.

    Article  PubMed  CAS  Google Scholar 

  43. de Zeeuw D: Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int Suppl 2004:S2–S6.

  44. Hillege HL, Fidler V, Diercks GF, et al.: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002, 106:1777–1782.

    Article  PubMed  CAS  Google Scholar 

  45. Neuschwander-Tetri BA, Caldwell SH: Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003, 37:1202–1219.

    Article  PubMed  Google Scholar 

  46. Hamaguchi M, Kojima T, Takeda N, et al.: The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005, 143:722–728.

    PubMed  CAS  Google Scholar 

  47. Athyros VG, Mikhailidis DP, Didangelos TP, et al.: Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006, 22:873–883.

    Article  PubMed  CAS  Google Scholar 

  48. Argo CK, Loria P, Caldwell SH, Lonardo A: Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 2008, 48:662–669.

    Article  PubMed  CAS  Google Scholar 

  49. Lewis JH, Mortensen ME, Zweig S, et al.: Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007, 46:1453–1463.

    Article  PubMed  CAS  Google Scholar 

  50. Ekstedt M, Franzen LE, Mathiesen UL, et al.: Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007, 47:135–141.

    Article  PubMed  CAS  Google Scholar 

  51. Grundy SM: Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient? Am J Med 2007, 120(9 Suppl 1):S3–S8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Krankenhausstrasse 12, 91054, Erlangen, Germany

    Roland E. Schmieder

Authors
  1. Christian Ott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roland E. Schmieder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roland E. Schmieder.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ott, C., Schmieder, R.E. The role of statins in the treatment of the metabolic syndrome. Current Science Inc 11, 143–149 (2009). https://doi.org/10.1007/s11906-009-0025-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-009-0025-6

Keywords

Search

Navigation